Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$3.67
-$0.36(-8.76%)
At close: 4:00 PM EDT
$3.67
-$0.36(-8.76%)
Day’s Range― - ―
52-Week Range$1.62 - $5.06
Previous CloseN/A
Volume791.73K
Average Volume (3M)669.84K
Market Cap
$112.57M
Enterprise Value$128.55M
Total Cash (Recent Filing)$26.69M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 16, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding43,295,770
10 Day Avg. Volume656,205
30 Day Avg. Volume669,838
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue37.87
Enterprise Value/Gross Profit115.91
Enterprise Value/Ebitda-5.88
Forecast
1Y Price Target
$35.00Price Target Upside853.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$5.68M
Bulls Say, Bears Say
Bulls Say
Ketamine Commercialization ReadinessCompletion of process validation and favorable long-term stability data advance the preservative-free ketamine candidate toward commercial readiness. These manufacturing and quality milestones can reduce approval execution risk and support a durable product launch platform if the FDA review is completed successfully.
DARPA-funded Clinical PlatformThe DARPA prime contract provides externally funded support for an FDA-approved Phase II/III trial combining NRX-101 with robotic TMS. It also gives NRx a government-backed development pathway and potential validation in treatment-resistant depression, military, veteran, and first-responder populations.
Expanded Development PipelineAdding two clinical-stage monoclonal antibodies broadens NRx beyond its existing CNS programs and creates additional shots on goal across ALS, multiple sclerosis, type 1 diabetes, and potential schizophrenia applications. A wider pipeline can improve long-term strategic value if development milestones are achieved.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that research, development, and corporate activities currently consume substantially more cash than the business generates. Unless revenue expands or spending declines, continued financing will be needed to maintain programs and support future commercialization.
Fragile Capital StructureNegative equity limits financial flexibility and indicates that accumulated losses have eroded the company’s capital base. Although reported debt is relatively low, the fragile structure increases reliance on external funding and may constrain NRx’s ability to absorb setbacks or finance several programs simultaneously.
Dependence On External Milestones And FundingImportant pipeline programs rely on government appropriations, competitive funding processes, and successful contracting rather than solely on internally generated cash. Delays or unsuccessful funding outcomes could slow clinical development, increase financing needs, and make the broader pipeline harder to advance on schedule.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $5.05 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $112.57M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 27 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Aug 17, 2026. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.333.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.21.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 43,295,770 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went up 4.893%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (853.68% Upside)
$35.00 (853.68% Upside)
Blogger Sentiment
Bearish
NRXP Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.47%
12-Months-Change
Fundamentals
Return on Equity
168.68%
Trailing 12-Months
Asset Growth
606.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant strategic and technical progress across multiple fronts: near-term commercialization steps (ANDA and launch-stock orders), a strengthened balance sheet (cash up ~242%), a materially expanded development pipeline via the GeNeuro acquisition, and a high-impact DARPA/military partnership with a 400-patient SPARC-TMS trial. These positives are tempered by ongoing net operating losses (operating loss up ~48.7%), regulatory/contracting uncertainties, dependence on nondilutive government funding, and the need for further financing or successful commercial milestones beyond the ~1-year cash runway. Overall, the tone is cautiously optimistic: strong strategic wins and funding momentum outweigh current financial and execution risks, but key approvals, contracts and trial execution remain critical near-term milestones.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$35.00
▲(853.68% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
3.12% Mutual Funds
11.35% Other Institutional Investors
79.50% Public Companies and
Individual Investors